Olaparib shows improvement in PFS but not OS, Thus Far

Olaparib, a PARP inhibitor, showed an 3.6 month improvement in progression free survival (PFS) in women with platinum sensitive recurrent ovarian cancer. However, based on the interim analsis, there is no significant improvement in overall survival. PARP inhibitors are presumed to work particularly well for patients with a BRCA mutation, however BRCA status was not required for enrollment in this trial.

See full article here